Original Article
Lack of Effect of Treating Helicobacter pylori Infection in Patients with Nonulcer Dyspepsia
N Engl J Med 1998; 339:1875-1881December 24, 1998
- Abstract
Background
It is uncertain whether treatment of Helicobacter pylori infection relieves symptoms in patients with nonulcer, or functional, dyspepsia.
Methods
We conducted a double-blind, multicenter trial of patients with H. pylori infection and dyspeptic symptoms (moderate-to-very-severe pain and discomfort centered in the upper abdomen). Patients were excluded if they had a history of peptic ulcer disease or gastroesophageal reflux disease and had abnormal findings on upper endoscopy. Patients were randomly assigned to seven days of treatment with 20 mg of omeprazole twice daily, 1000 mg of amoxicillin twice daily, and 500 mg of clarithromycin twice daily or with omeprazole alone and then followed up for one year. Treatment success was defined as the absence of dyspeptic symptoms or the presence of minimal symptoms on any of the 7 days preceding the 12-month visit.
Results
Twenty of the 348 patients were excluded after randomization because they were not infected with H. pylori, were not treated, or had no data available. For the remaining 328 patients (164 in each group), treatment was successful for 27.4 percent of those assigned to receive omeprazole and antibiotics and 20.7 percent of those assigned to receive omeprazole alone (P=0.17; absolute difference between groups, 6.7 percent; 95 percent confidence interval, –2.6 to 16.0). After 12 months, gastritis had healed in 75.0 percent of the patients in the group given omeprazole and antibiotics and in 3.0 percent of the patients in the omeprazole group (P<0.001); the respective rates of H. pylori eradication were 79 percent and 2 percent. In the group given omeprazole and antibiotics, the rate of treatment success among patients with persistent H. pylori infection was similar to that among patients in whom the infection was eradicated (26 percent vs. 31 percent). There were no significant differences between the groups in the quality of life after treatment.
Conclusions
In patients with nonulcer dyspepsia, the eradication of H. pylori infection is not likely to relieve symptoms.
Media in This Article
Figure 2
Mean Symptom Scores during the Seven-Day Run-in Period (Base Line) and during the Seven Days before Each Follow-up Clinic Visit.Figure 3
Mean Scores for the Psychological General Well-Being Index at Base Line and after Treatment with Omeprazole and Antibiotics or Omeprazole Alone.Article Activity
- Article
Approximately one third of people in industrialized nations have recurrent dyspeptic symptoms, or dyspepsia, many of whom have no evidence of chronic peptic ulceration, reflux esophagitis, a malignant condition, or other defined organic disease.1-4 The ambiguity in the diagnosis has led to the development of various definitions of dyspepsia, dyspeptic symptoms, and nonulcer, or functional, dyspepsia, based on available clinical, epidemiologic, and pathophysiologic data.5 Nonulcer dyspepsia is defined as “persistent or recurrent abdominal pain or discomfort centered in the upper abdomen in patients who have no definite structural or biochemical explanation for their symptoms (e.g., peptic ulcer disease, gastroesophageal reflux disease, malignancy or pancreaticobiliary disease).”6 The pathogenesis of nonulcer dyspepsia is unknown, but disturbances of visceral perception, gastric acid secretion, and gastroduodenal motility, as well as H. pylori infection, have been implicated.7 The reported prevalence of H. pylori infection in patients with gastritis and nonulcer dyspepsia ranges from 30 to 70 percent.3,8 As yet, however, it is uncertain whether H. pylori infection causes the dyspeptic symptoms in these patients.
We compared the effect of one week of treatment with omeprazole, amoxicillin, and clarithromycin with that of one week of treatment with omeprazole alone on the relief of symptoms, eradication of H. pylori infection, healing of gastritis, and quality of life in patients with nonulcer dyspepsia. Given the evidence that regression of H. pylori–induced gastritis could take at least 1 year after the successful cure of the infection,9 we followed the patients for 12 months.
Methods
Study Design
This randomized, double-blind study was conducted in numerous centers in Austria, Canada, Germany, Iceland, Ireland, South Africa, and Sweden between December 1995 and December 1997, according to the principles of good clinical practice and in accordance with the revised Declaration of Helsinki. The study protocol and patient information and consent form were approved by an independent ethics committee at each study center, and written informed consent was obtained from the patients before enrollment.
Selection of Patients
Patients who sought medical care for dyspeptic symptoms (specifically, pain or discomfort centered in the upper abdomen) that had been present for at least six months and who had no history of peptic ulcer disease or gastroesophageal disease were eligible for the study, provided they had normal endoscopic findings (i.e., five or fewer gastric erosions and no esophageal, gastric, or duodenal ulcers, esophageal or duodenal erosions, or Barrett's esophagus) and were H. pylori–positive on analysis with the rapid urease test (HUT, Astra, Wedel, Germany). After enrollment, blood samples were obtained for routine laboratory screening, to check for any chemical or hematologic abnormalities. Patients were given diary cards and asked to evaluate their dyspeptic symptoms at bedtime each evening for a run-in period of seven days, during which they received no treatment. The symptoms were graded with use of a validated seven-point Likert10 scale as absent (score of 0), minimal (1), mild (2), moderate (3), moderately severe (4), severe (5), or very severe (6). Only patients with moderate-to-very-severe pain or discomfort centered in the upper abdomen on at least three days during the run-in period underwent randomization in blocks of two, according to a computer-generated list. Patients with unintentional weight loss, dysphagia, hematemesis, or any other signs indicating serious disease were excluded. Treatment with histamine H2-receptor antagonists, prostaglandins, or prokinetic agents during the seven days before entry into the study was not permitted, nor was treatment with proton-pump inhibitors, antibiotics, or bismuth-containing compounds during the month before the study began.
Study Protocol
At the end of the one-week run-in period, patients who fulfilled the selection criteria were randomly assigned to one week of treatment with either 20 mg of omeprazole (Losec, Astra, Södertälje, Sweden) twice daily (morning and evening), 1000 mg of amoxicillin (Amimox, Astra) twice daily, and 500 mg of clarithromycin (Bremón, Abbott Laboratories, Madrid, Spain) twice daily or 20 mg of omeprazole twice daily, as well as placebo antibiotics. The treatments were given orally in a double-blind fashion, and active and placebo tablets were identical in appearance. The patients returned to the clinic after 1 week and 1, 3, 6, 9, and 12 months after the end of treatment.
Endoscopy, Biopsy, and the Urea Breath Test
Endoscopy and biopsy were performed before the run-in period and 3 and 12 months after treatment was completed. Two biopsy specimens of the antrum, corpus, and angulus were obtained for histologic analysis at each visit, and one additional specimen of the antrum and the corpus was obtained during the preliminary endoscopy for the rapid urease test. The patients also underwent a urea breath test11 at the end of the run-in period and again 3 and 12 months after treatment to confirm their H. pylori status. Patients were regarded as positive for H. pylori at randomization if they had a positive rapid urease test and a positive urea breath test or abnormal histologic findings (or both). At the 3-month and 12-month follow-up visits, patients were regarded as positive for H. pylori if they had a positive urea breath test, abnormal histologic findings, or both. In the case of patients who did not take these tests or whose data were lost, the H. pylori status was defined as unknown. Neither the patients nor the investigators were aware of the patients' H. pylori status during the study.
Histologic Analysis
The biopsy specimens were embedded in paraffin and cut into 4-μm sections perpendicularly to the mucosal surface. They were then stained with hematoxylin and eosin and Warthin–Starry silver, and the severity of gastritis was graded according to the Houston modification of the Sydney system.12
Assessment of the Quality of Life
We assessed the patients' quality of life on four occasions during the study — at randomization, after the completion of treatment, and at the 6-month and 12-month follow-up visits — with the use of two validated questionnaires. The Gastrointestinal Symptom Rating Scale assesses the severity of indigestion, diarrhea, constipation, abdominal pain, and reflux, and scores can range from 1 (no symptoms) to 7 (severe symptoms).13 The Psychological General Well-Being Index14 measures subjective well-being in terms of anxiety, depressed mood, positive well-being, self-control, and general health and vitality. The worst possible score is 22, and the best possible is 132. We also assessed the overall effect of treatment 6 and 12 months after it had ended by comparing the severity of dyspeptic symptoms before and after treatment with a Likert scale in which a score of –6 indicated that symptoms were “a great deal worse,” a score of 0 that symptoms were “about the same,” and a score of 6 that symptoms were “a very great deal better.”
Statistical Analysis
The sample size was calculated to allow two primary comparisons between the groups: the relief of dyspeptic symptoms and healing of gastritis. The significance level was adjusted to 2.5 percent for each comparison with the Bonferroni correction.15 The assumed rate of treatment success was 40 percent in the group assigned to receive omeprazole and antibiotics and 20 percent in the group assigned to receive omeprazole alone. With the use of a two-sided test and a power of 80 percent for the comparison of dyspeptic symptoms, the study required a total of 320 patients (160 patients in each group), up to 25 percent of whom could be deemed unable to be evaluated. With a sample of this size, the power of the study to detect differences in the rates of healing of gastritis was about 95 percent. The healing rates were assumed to be 50 percent in the group assigned to receive omeprazole and antibiotics and 20 percent in the group assigned to receive omeprazole alone.
The intention-to-treat analyses included all patients who received at least one dose of medication and who were H. pylori–positive at entry. In the analyses per protocol, all patients with major deviations from the protocol (use of prohibited drugs before study entry, insufficiently severe symptoms during the run-in period, abnormal findings on pre-entry endoscopy, and history of peptic ulcer disease) were excluded. For the predetermined primary evaluation, treatment was considered successful if a patient reported no symptoms or no more than minimal pain or discomfort centered in the upper abdomen during any of the 7 days preceding the 12-month visit (a score of 0 or 1) on the daily diary cards. The other main response variable was healing of gastritis. Treatment success and healing of gastritis were compared between groups with a Mantel–Haenszel test16 stratified according to country. The effects of the countries were assessed with the Breslow–Day test.16 The proportion of patients in whom H. pylori infection was eradicated was estimated, and values are given with 95 percent confidence intervals. The quality-of-life scores were compared between the two groups with the use of analysis of variance, with base-line scores included as a covariate.
Results
Patient Population
We screened 466 patients and excluded 118. Of the 348 patients who were randomly assigned to a treatment group, 328 were included in the intention-to-treat analysis and 245 were included in the per-protocol analysis (Figure 1Figure 1
Numbers of Patients Enrolled in the Study and Analyzed According to the Intention to Treat or per Protocol.). The reasons for exclusion from the analyses are given in Figure 1. The base-line characteristics of the two treatment groups were similar (Table 1Table 1
Base-Line Characteristics of the 328 Patients Included in the Intention-to-Treat Analysis.).Treatment Success and Healing of Gastritis
The rates of treatment success and healing of gastritis are given in Table 2Table 2
Rates of Successful Treatment and Healing of Gastritis, According to the Intention-to-Treat Analysis and Analysis per Protocol.. The rates of treatment success were similar in the group given omeprazole, amoxicillin, and clarithromycin and the group given omeprazole alone whether they were analyzed according to the intention to treat (27.4 percent vs. 20.7 percent; absolute difference between groups, 6.7 percent; 95 percent confidence interval, –2.6 to 16.0) or per protocol (28.2 percent vs. 24.0 percent; absolute difference between groups, 4.3 percent; 95 percent confidence interval, –6.8 to 15.3). A Breslow–Day test showed no indication of any inhomogeneity in the results according to the country in which patients were treated (P>0.7) in either analysis.The proportions of patients with no symptoms or minimal symptoms (as recorded on the diary cards) during the 7 days before each visit at 6, 9, or 12 months were not significantly different between the two groups whether the data for each time point were analyzed separately or together (13 percent in the group given omeprazole and antibiotics and 10 percent in the group given omeprazole alone; P=0.61 by two-sided Fisher's exact test). Similarly, when the mean symptom scores (Figure 2Figure 2
Mean Symptom Scores during the Seven-Day Run-in Period (Base Line) and during the Seven Days before Each Follow-up Clinic Visit.) for the visits at 6, 9, and 12 months were compared, there was no significant difference between groups (1.73 in the group given omeprazole and antibiotics and 1.74 in the group given omeprazole alone; P=0.9).The proportion of patients without gastritis at 12 months was significantly higher in the group given omeprazole and antibiotics than in the group given omeprazole alone (75.0 percent vs. 3.0 percent; P<0.001, according to the intention-to-treat analysis) (Table 2). The results were similar when the data were analyzed per protocol (Table 2).
Quality of Life
In both groups, the patients' quality of life improved after treatment, but not significantly. Overall, the mean scores for the Psychological General Well-Being Index (Figure 3Figure 3
Mean Scores for the Psychological General Well-Being Index at Base Line and after Treatment with Omeprazole and Antibiotics or Omeprazole Alone.) and the Gastrointestinal Symptom Rating Scale (data not shown) improved, but there were no significant differences between groups whether the data were analyzed separately for each portion of the scale or for the total score. With respect to the overall effect of treatment, two thirds of the patients in each group reported an improvement in symptoms; the other third indicated that they felt about the same as they had at entry.Eradication of H. pylori Infection
According to the intention-to-treat analysis, H. pylori infection was eradicated in 79 percent (95 percent confidence interval, 72 to 85 percent) of the patients in the group given omeprazole and antibiotics (because of missing data, the outcome was unknown for 9 percent) and 2 percent (95 percent confidence interval, 1 to 7 percent) of the patients in the group given omeprazole alone (the outcome was unknown for 10 percent). In the group given omeprazole and antibiotics, 31 percent of those who were cured had relief of symptoms, as compared with 26 percent of those who remained H. pylori–positive. According to the analysis per protocol, which excluded patients for whom the outcome was unknown, H. pylori infection was eradicated in 87 percent of the patients (108 of 124) in the group given omeprazole and antibiotics.
Relation among Healing of Gastritis, Eradication of Infection, and Treatment Success
In the group given omeprazole and antibiotics, 119 of the patients had healing of gastritis and eradication of H. pylori infection. The rate of treatment success in this subgroup was 30 percent, as compared with a rate of 29 percent among the 14 patients in whom gastritis did not resolve and H. pylori was not eradicated. The remaining 31 patients in this group had either healing of gastritis or eradication of H. pylori infection, but not both, or had data missing. In the group given omeprazole alone, 137 of the patients remained positive for H. pylori and had unhealed gastritis. The rate of treatment success in this subgroup was 23 percent, as compared with a rate of 0 percent among the three patients with resolution of gastritis and eradication of infection. The remaining 24 patients in this group had either healing of gastritis or eradication of H. pylori infection, but not both, or had data missing.
At the 12-month follow-up visits, 11 patients in the group given omeprazole and antibiotics had lesions (10 had erosive esophagitis and 1 had a gastric ulcer), as compared with 9 patients in the group given omeprazole alone (3 had erosive esophagitis, 4 had gastric ulcers, and 2 had duodenal ulcers).
Evaluation of Safety
Safety data were available for 169 patients in the group given omeprazole and antibiotics and 176 patients in the group given omeprazole alone. There were no serious adverse events in either group during treatment. Few patients had treatment stopped because of an adverse event: 12 in the group given omeprazole and antibiotics and 2 in the group given omeprazole alone. The most common adverse event, diarrhea, occurred in 63 patients in the group given omeprazole and antibiotics and in 10 patients in the group given omeprazole alone.
Discussion
Peptic ulcer disease is strongly associated with H. pylori infection. The eradication of this infection prevents relapse of gastric and duodenal ulcers, unless reinfection occurs or patients take ulcerogenic drugs such as nonsteroidal antiinflammatory drugs.17,18 A role for H. pylori in nonulcer dyspepsia also seems plausible, and numerous studies have investigated a possible link. However, the results of clinical trials have so far been equivocal, and the role of H. pylori remains highly controversial.7,19,20 In a recent critique of 16 therapeutic trials in patients with nonulcer dyspepsia who had H. pylori infection,21 all of the studies were considered to have at least one serious methodologic weakness. Our study guidelines were drawn up after a systematic review of trial methods.22
We used a strict definition of nonulcer dyspepsia,6 since this was one of the major variants in previous studies. It can be argued that if the entry criteria are too strict, the study group is not truly representative of people with dyspepsia, but the use of more relaxed criteria may result in the inclusion of patients with other gastrointestinal diseases, such as gastroesophageal reflux disease and peptic ulcer disease. The inclusion of patients with gastroesophageal reflux disease may decrease the chance of a positive response, whereas the inclusion of patients with peptic ulcer disease may increase the chance of a positive response.
We based our sample size on careful predictions of efficacy and included a 12-month period of follow-up, which is sufficient time to allow healing of gastritis.9 H. pylori infection was detected with the use of validated methods11,12 and treated optimally with omeprazole, amoxicillin, and clarithromycin,23,24 and both patients and physicians were unaware of the patients' H. pylori status at follow-up. The rather low rate of eradication of H. pylori infection in the intention-to-treat analysis of the group given omeprazole and antibiotics was for the most part accounted for by the relatively large proportion (9 percent) of patients for whom the outcome was unknown.
Studies of nonulcer dyspepsia have often been criticized for failing to use validated outcome measures.22 We used a stringent definition of treatment success: the absence of symptoms or the presence of only minimal symptoms. As a means of determining the response, we used a Likert scale to assess the severity of symptoms25,26 as well as the Gastrointestinal Symptom Rating Scale and the Psychological General Well-Being Index, both of which have been validated and widely used in different countries,13,14,27-29 to assess the patients' quality of life.
There were no significant differences in the rates of symptom relief or other secondary variables between the two treatment groups during the 12 months of follow-up, and there was also no apparent difference in the rates of treatment success between patients in whom gastritis had healed and H. pylori was eradicated and those with persistent gastritis and infection. Although the quality of life after treatment did not differ significantly between the two groups, both groups had a marked improvement in all the variables analyzed in this assessment, including the severity of dyspeptic symptoms, as reported previously in many other studies.21,30,31 This finding confirms that we used sensitive instruments of assessment.
In studies of nonulcer dyspepsia, the use of repeated endoscopy is important to rule out the possibility of a high incidence of ulcers at follow-up. In our study, fewer than 3 percent of patients had peptic ulcers at follow-up and all but one of the ulcers occurred in patients with persistent H. pylori infection. These results suggest that we did not include patients who had peptic ulcer disease but had no evidence of it on endoscopy and instead included only patients with non-ulcer dyspepsia. We conclude that although the eradication of H. pylori infection may help prevent or cure peptic ulcer disease, it is not likely to have a major role in the treatment of symptoms in patients with nonulcer dyspepsia.
Supported by Astra Hässle and by a grant (31.43240.95) from the Swiss National Foundation of Science (to Dr. Blum).
Drs. Stolte and Theodórs have been consultants for Astra Hässle. Dr. Talley has been a consultant for Astra Hässle and for Abbott Laboratories.
We are indebted to Dr. Madeline Frame for assistance with the drafting and editing of the manuscript; to Dr. Jörgen Naesdal, who was medical advisor for the Dyspepsia Group at Astra Hässle; and to all other personnel who took part in the study.
Source Information
From the Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (A.L.B.); the Department of Medicine, University of Sydney and Nepean Hospital, Sydney, Australia (N.J.T.); the Department of Gastroenterology, Meath–Adelaide Hospitals, Trinity College, Dublin, Ireland (C.O.); the Division of Gastroenterology, Queen Elizabeth II Health Sciences Center, Halifax, N.S., Canada (S.V.Z.); Uni-Klinik Otto von Guericke, Gastroenterologie, Magdeburg, Germany (J.L.); the Institute for Pathology, Klinikum Bayreuth, Bayreuth, Germany (M.S.); the Department of Gastroenterology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa (J.A.L.); the Department of Surgery, Värnamo Hospital, Värnamo, Sweden (A.S.); the Division of Gastroenterology, St. Josph's Hospital, Hafnarfjordur, Iceland (A.T.); the Departments of Clinical Research (M.S., E.B.-S.) and Statistics (O.J.), Astra Hässle, Mölndal, Sweden; and the Department of Biomedicine and Surgery, Linköping Hospital, Linköping, Sweden (E.B.-S.).
Address reprint requests to Dr. Blum at the Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland.
Other members of the Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment Study Group are listed in the Appendix.
Appendix
In addition to the authors, other members of the Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment Study Group were as follows: Austria — G. Brandstätter; Canada — K. Peltekian, B. Badley, J. Love, D. Leddin, C. Williams, B. O'Brien, A. Barkun, S. Mayrand, D. Daly, D. Cleland, N. Chiba, A. Cockeram, H. Conter, M. Trager, A. Cameron, J. Graham, M. Burnstein, C. Dallaire, B. Rousseau, J. Deneault, W. Depew, J. Simon, W. Paterson, P. Gagnon, G. Routhier, O. Gagnon, J. Michaud, D. MacIntosh, J. Fardy, R. Bursey, N. Marcon, G. Kandel, G. Haber, P. Kortan, G. Morgan, J. Milton, P. Pare, R. Dubé, D. Lévesque, M. Bradette, M. Boivin, P. Poitras, I. Prokopiw, R. Reynolds, M. Belsheim, H. Preksaitis, D. Lloyd, L. Cohen, F. Saibil, D. Hemphill, H. Steinhart, D. Baron, R. Ward, D. Putnam, R. May, A. Watier, J. Dubois, H. Haddad; Germany — M. Menges, W. Brandt, H.-U. Klör, P. Hardt, M. Özcürümez, W. Doppl, H. Schnell-Kretschmer, H. Wurzer, H. Ahrens, L.-H. Griem, U. Pannewick, B. Marowski, H.-J. Schulz, I. Ajer, N. Städler, K. Gail, B. Albrecht, A. Velthof, M. Frömmel; Iceland — K. Örvar, S. Kristjánsdóttir, Ó. Gunnlaugsson, B. Þjóðleifsson, H. Guðjónsson, A. Böðvarsson, S. Ólafsson; Ireland — M. Buckley, J. Lee, N. Breslin, C. Fallon, C. Forkin, D. McNamara, S. Montague, D. Weir, B. Ryan, N. Mahmud, S. McKiernan, D. O'Toole, D. Kelleher, V. Pippet; South Africa — T. Winter, A. Cariem, W. Osler, G. Smit, G. Adams, C. van Rensburg, A. Thorpe, E. Wilken, A. Simjee, F. Makumbi, P. Soni; and Sweden — K. Melén, B. Bergman, L. Carling, L. Svedberg, H. Törnblom, G. Engström, P. Götell, H. Forsell, B. Ohlin, B. Hallerbäck, E. Johnsson, T. Hallgren, O. Anker-Hansen, M. Hellblom, B. Jaup, I. Kagevi, T. Lind, C. Lindström, G. Lundegårdh, J. Martinsson, E. Tveit, P. Unge, and P. Park.
- References
References
1
Jones R ,Lydeard S . Prevalence of symptoms of dyspepsia in the community. BMJ 1989;298:30-32
CrossRef | Web of Science | Medline2
Bernersen B ,Johnsen R ,Bostad L ,Straume B ,Sommer AI ,Burhol PG . Is Helicobacter pylori the cause of dyspepsia? BMJ 1992;304:1276-1279
CrossRef | Web of Science | Medline3
Armstrong D . Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl 1996;215:38-47
CrossRef | Medline4
Bytzer P . Diagnosing dyspepsia: any controversies left? Gastroenterology 1996;110:302-306
CrossRef | Web of Science | Medline5
Heading RC . Definitions of dyspepsia. Scand J Gastroenterol Suppl 1991;182:1-6
CrossRef | Medline6
Talley NJ ,Colin-Jones D ,Koch KL ,Koch M ,Nyren O ,Stanghellini V . Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991;4:145-1607
Pantoflickova D ,Koelz HR ,Blum AL . Helicobacter pylori and functional dyspepsia: a real causal link? Baillieres Clin Gastroenterol 1998;12:503-532
CrossRef | Web of Science | Medline8
Schubert TT ,Schubert AB ,Ma CK . Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy. Gastrointest Endosc 1992;38:357-360
CrossRef | Web of Science | Medline9
Verdu EF ,Armstrong D ,Idstrom JP , et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996;31:1151-1156
CrossRef | Web of Science | Medline10
Junghard O, Talley NJ, Wiklund I. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg (in press).
11
Dominguez-Munoz JE ,Leodolter A ,Sauerbruch T ,Malfertheiner P . A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997;40:459-462
Web of Science | Medline12
Dixon MF ,Genta RM ,Yardley JH ,Correa P . Classification and grading of gastritis: the updated Sydney system: International Workshop on the Histology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181
CrossRef | Web of Science | Medline13
Svedlund J ,Sjodin I ,Dotevall G . GSRS -- a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-134
CrossRef | Web of Science | Medline14
Wenger NK ,Mattson ME ,Furberg CF ,Elinson J . Assessment of quality of life in clinical trials of cardiovascular therapies. Am J Cardiol 1984;54:908-913
CrossRef | Web of Science | Medline15
Toothaker LE. Multiple comparisons for researchers. Newbury Park, Calif.: Sage, 1991.
16
Agresti A. An introduction to categorical data analysis. New York: John Wiley, 1996.
17
Goh K-L ,Navaratnam P ,Peh S-C . Reinfection and duodenal ulcer relapse in South-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. Eur J Gastroenterol Hepatol 1996;8:1157-1160
CrossRef | Web of Science | Medline18
Sontag SJ . Guilty as charged: bugs and drugs in gastric ulcer. Am J Gastroenterol 1997;92:1255-1261
Web of Science | Medline19
Veldhuyzen van Zanten SJO . The role of Helicobacter pylori infection in non-ulcer dyspepsia. Aliment Pharmacol Ther 1997;11:Suppl 1:63-69
CrossRef | Web of Science | Medline20
Talley NJ ,Hunt RH . What role does Helicobacter pylori play in dyspepsia and in nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997;113:Suppl:S67-S77
CrossRef | Web of Science | Medline21
Talley NJ . A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994;106:1174-1183
Web of Science | Medline22
Veldhuyzen van Zanten SJO ,Cleary C ,Talley NJ , et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-673
Web of Science | Medline23
Lind T ,Veldhuyzen van Zanten S ,Unge P , et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the Mach I Study. Helicobacter 1996;1:138-144
CrossRef | Medline24
Lind T ,Megraud F ,Bardhan KD , et al. The MACH2 study: antimicrobial resistance in Helicobacter pylori therapy -- the impact of omeprazole. Gut 1997;41:Suppl 1:A89-A89 abstract.
Web of Science25
Veldhuyzen van Zanten SJO ,Tytgat KM ,Pollak PT , et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993;46:273-279
CrossRef | Web of Science | Medline26
Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford, England: Oxford University Press, 1989.
27
Dimenas E ,Glise H ,Hallerback B ,Hernqvist H ,Svedlund J ,Wiklund I . Quality of life in patients with upper gastrointestinal symptoms: an improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-687
CrossRef | Web of Science | Medline28
Dimenas E ,Glise H ,Hallerback B ,Hernqvist H ,Svedlund J ,Wiklund I . Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-1052
CrossRef | Web of Science | Medline29
Wiklund I ,Halling K ,Langstrom G . The Psychological General Well-Being (PGWB) index, a reliable tool for use in cross-cultural multicentre clinical trials. Qual Life Res 1995;4:503-503 abstract.30
Blum AL, Arnold R, Koelz HR, Stolte M, FROSCH Study Group
CrossRef | Web of Science31
Talley NJ ,Meineche-Schmidt V ,Pare P , et al. Is acid suppression efficacious in non-ulcer dyspepsia? A doubleblind, randomised, controlled trial with omeprazole. Gastroenterology 1998;114:A305-A305 abstract.
CrossRef | Web of Science
- Citing Articles (181)
Citing Articles
1
Nicholas J. Talley, G. Richard Locke, Linda M. Herrick, Vickie M. Silvernail, Charlene M. Prather, Brian E. Lacy, John K. DiBaise, Colin W. Howden, Darren M. Brenner, Ernest P. Bouras, Hashem B. El-Serag, Bincy P. Abraham, Paul Moayyedi, Alan R. Zinsmeister. (2012) Functional Dyspepsia Treatment Trial (FDTT): A double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemporary Clinical Trials
CrossRef2
S. E. Titov, G. V. Panasyuk, M. K. Ivanov, G. M. Dymshits. (2011) Detection of Helicobacter pylori in bioptates of gastric mucosa of patients with gastritis and gastric ulcers using real-time PCR. Molecular Genetics, Microbiology and Virology 26:3, 126-131
CrossRef3
Hidekazu Suzuki, Toshihiro Nishizawa, Toshifumi Hibi. (2011) Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia?. Journal of Gastroenterology and Hepatology 26, 42-45
CrossRef4
Hiroto Miwa, Jiro Watari, Hirokazu Fukui, Tadayuki Oshima, Toshihiko Tomita, Jun Sakurai, Takashi Kondo, Takayuki Matsumoto. (2011) Current understanding of pathogenesis of functional dyspepsia. Journal of Gastroenterology and Hepatology 26, 53-60
CrossRef5
D. Ang, N. J. Talley, M. Simren, P. Janssen, G. Boeckxstaens, J. Tack. (2011) Review article: endpoints used in functional dyspepsia drug therapy trials. Alimentary Pharmacology & Therapeutics 33:6, 634-649
CrossRef6
Paul Moayyedi, Shelly Soo, Jonathan J Deeks, Brendan Delaney, Adam Harris, Michael Innes, R Oakes, Sue Wilson, A Roalfe, Cathy Bennett, David Forman, Paul Moayyedi. 2011. Eradication of Helicobacter pylori for non-ulcer dyspepsia. .
CrossRef7
Paul Moayyedi, Jose Santana, Mostafiz Khan, Cathy Preston, Clare Donnellan, Paul Moayyedi. 2011. Medical treatments in the short term management of reflux oesophagitis. .
CrossRef8
Sam Ryong Jee, Hye-Kyung Jung, Byung Hoon Min, Kee Don Choi, Poong-Lyul Rhee, Young Woo Kang, Sang In Lee, . (2011) Guidelines for the Treatment of Functional Dyspepsia. The Korean Journal of Gastroenterology 57:2, 67
CrossRef9
K. Matsueda, M. Hongo, S. Ushijima, H. Akiho. (2011) A Long-Term Study of Acotiamide in Patients with Functional Dyspepsia: Results from an Open-Label Phase III Trial in Japan on Efficacy, Safety and Pattern of Administration. Digestion 84:4, 261-268
CrossRef10
Seiji Futagami, Mayumi Shimpuku, Yan Yin, Tomotaka Shindo, Yasuhiro Kodaka, Hiroyuki Nagoya, Shoko Nakazawa, Mayumi Fujimoto, Nikki Izumi, Noriko Ohishi, Tetsuro Kawagoe, Akane Horie, Katsuhiko Iwakiri, Choitsu Sakamoto. (2011) Pathophysiology of Functional Dyspepsia. Journal of Nippon Medical School 78:5, 280-285
CrossRef11
Kentaro Sugano. (2011) Should We Still Subcategorize Helicobacter pylori -Associated Dyspepsia as Functional Disease?. Journal of Neurogastroenterology and Motility 17:4, 366
CrossRef12
Gati Dhroove, Ashish Chogle, Miguel Saps. (2010) A Million-dollar Work-up for Abdominal Pain: Is It Worth It?. Journal of Pediatric Gastroenterology and Nutrition 51:5, 579-583
CrossRef13
Seiji Futagami, Tomotaka Shindo, Tetsuro Kawagoe, Akane Horie, Mayumi Shimpuku, Katya Gudis, Katsuhiko Iwakiri, Takashi Itoh, Choitsu Sakamoto. (2010) Migration of Eosinophils and CCR2-/CD68-Double Positive Cells Into the Duodenal Mucosa of Patients With Postinfectious Functional Dyspepsia. The American Journal of Gastroenterology 105:8, 1835-1842
CrossRef14
Masahiro Asaka, Mototsugu Kato, Shin-ichi Takahashi, Yoshihiro Fukuda, Toshiro Sugiyama, Hiroyoshi Ota, Naomi Uemura, Kazunari Murakami, Kiichi Satoh, Kentaro Sugano. (2010) Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition. Helicobacter 15:1, 1-20
CrossRef15
Tseng-Shing Chen, Jiing-Chyuan Luo, Full-Young Chang. (2010) Psychosocial-spiritual factors in patients with functional dyspepsia: a comparative study with normal individuals having the same endoscopic features. European Journal of Gastroenterology & Hepatology 22:1, 75-80
CrossRef16
Shigeaki Yasaka, Kazunari Murakami, Takashi Abe, Juro Anan, Kazuhiro Mizukami, Jin Tanahashi, Tadayoshi Okimoto, Masaaki Kodama, Yoshikuni Kudo, Hisanori Kawasaki, Toshio Fujioka. (2009) Evaluation of esophageal function in patients with gastroesophageal reflux disease using transnasal endoscopy. Journal of Gastroenterology and Hepatology 24:10, 1677-1682
CrossRef17
Aamir Saleem, Asghar Qasim, Humphrey J O’Connor, Colm A O’Morain. (2009) Pylera ® for the eradication of Helicobacter pylori infection. Expert Review of Anti-infective Therapy 7:7, 793-799
CrossRef18
Kok-Ann Gwee, Leyan Teng, Reuben-KM Wong, Khek-Yu Ho, Dede-Selamat Sutedja, Khay-Guan Yeoh. (2009) The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. European Journal of Gastroenterology & Hepatology 21:4, 417-424
CrossRef19
Christo van Rensburg, Peter Berghöfer, Robert Enns, I Dan Dattani, Johannes F Maritz, Pedro Gonzalez Carro, Renate Fischer, Thomas Schwan. (2008) Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia*. Current Medical Research and Opinion 24:7, 2009-2018
CrossRef20
J. G. HASHASH, H. ABDUL-BAKI, C. AZAR, I. I. ELHAJJ, L. EL ZAHABI, H. F. CHAAR, A. I. SHARARA. (2008) Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. Alimentary Pharmacology & Therapeutics 27:11, 1148-1155
CrossRef21
Michael Selgrad, Arne Kandulski, Peter Malfertheiner. (2008) Dyspepsia and <i>Helicobacter pylori</i>. Digestive Diseases 26:3, 210-214
CrossRef22
William D. Chey, Benjamin C.Y. Wong, . (2007) American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. The American Journal of Gastroenterology 102:8, 1808-1825
CrossRef23
Larry H. Lai, Joseph J.Y. Sung. (2007) Helicobacter pylori and benign upper digestive disease. Best Practice & Research Clinical Gastroenterology 21:2, 261-279
CrossRef24
David A. Peura, Jeff Gudmundson, Nancy Siepman, Betsy L. Pilmer, James Freston. (2007) Proton Pump Inhibitors: Effective First-Line Treatment for Management of Dyspepsia. Digestive Diseases and Sciences 52:4, 983-987
CrossRef25
Heng Yu Wong, Emeran A. Mayer. 2007. El dolor abdominal en la práctica clínica. , 775-800.
CrossRef26
Panagiotis Katsinelos, Kostas Tziomalos, Grigoris Chatzimavroudis, Themistoklis Vasiliadis, Taxiarchis Katsinelos, Ioannis Pilpilidis, Ioannis Triantafillidis, George Paroutoglou, Basilis Papaziogas. (2007) Eradication Therapy in <i>Helicobacter pylori</i>-Positive Patients with Halitosis: Long-Term Outcome. Medical Principles and Practice 16:2, 119-123
CrossRef27
Charles N. Bernstein. (2006) The Placebo Effect for Gastroenterology: Tool or Torment. Clinical Gastroenterology and Hepatology 4:11, 1302-1308
CrossRef28
Paul Moayyedi, Soo Shelly, Jonathan J Deeks, Brendan Delaney, Michael Innes, David Forman, Paul Moayyedi. 2006. Pharmacological interventions for non-ulcer dyspepsia. .
CrossRef29
Andrea Morgner, Joachim Labenz, Stephan Miehlke. (2006) Effective regimens for the treatment of Helicobacter pylori infection. Expert Opinion on Investigational Drugs 15:9, 995-1016
CrossRef30
Hidekazu Suzuki, Toshihiro Nishizawa, Toshifumi Hibi. (2006) Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. Journal of Gastroenterology 41:6, 513-523
CrossRef31
André JPM Smout. (2006) Advantages and disadvantages of lumping together gastroesophageal reflux disease and dyspepsia. Current Opinion in Gastroenterology 22:4, 412-416
CrossRef32
T. SUZUKI, K. MATSUO, A. SAWAKI, H. ITO, K. HIROSE, K. WAKAI, S. SATO, T. NAKAMURA, K. YAMAO, R. UEDA, K. TAJIMA. (2006) Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 24:2, 273-280
CrossRef33
N. VAKIL, N. J. TALLEY, M. STOLTE, M. SUNDIN, O. JUNGHARD, E. BOLLING-STERNEVALD. (2006) Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics 24:1, 55-63
CrossRef34
Dorte Ejg Jarbol, Mickael Bech, Jakob Kragstrup, Troels Havelund, Ove B. Schaffalitzky de Muckadell. (2006) Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori for management of dyspepsia: A randomized trial in primary care. International Journal of Technology Assessment in Health Care 22:03,
CrossRef35
Tadayuki Oshima, Hiroto Miwa. (2006) Treatment of functional dyspepsia: where to go and what to do. Journal of Gastroenterology 41:7, 718-719
CrossRef36
Tiing Leong Ang, Kwong Ming Fock, Eng Kiong Teo, Yiong Huak Chan, Tay Meng Ng, Tju Siang Chua, Jessica Yi-Lyn Tan. (2006) Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. Journal of Gastroenterology 41:7, 647-653
CrossRef37
C. Toro, M. L. Caballero, M. Baquero, J. Garcia-Samaniego, I. Casado, P. Martinez, T. Alarcon, I. Moneo. (2006) Seropositivity to a major allergen of Anisakis simplex, Ani s 1, in dyspeptic patients with Helicobacter pylori infection: histological and laboratory findings and clinical significance. Clinical Microbiology and Infection 12:5, 453-458
CrossRef38
Paul Moayyedi, Shelly Soo, Jonathan J Deeks, Brendan Delaney, Adam Harris, Michael Innes, R Oakes, Sue Wilson, A Roalfe, Cathy Bennett, David Forman, Paul Moayyedi. 2006. Eradication of Helicobacter pylori for non-ulcer dyspepsia. .
CrossRef39
Rocco Roberto Pidoto, Fausto Fama’, Giuseppa Giacobbe, Maria Antonietta Gioffre’ Florio, Andrea Cogliandolo. (2006) Quality of life and predictors of long-term outcome in patients undergoing open Nissen fundoplication for chronic gastroesophageal reflux. The American Journal of Surgery 191:4, 470-478
CrossRef40
S. J. O. VELDHUYZEN ZANTEN, N. CHIBA, D. ARMSTRONG, A. N. BARKUN, A. B. R. THOMSON, V. MANN, S. ESCOBEDO, B. CHAKRABORTY, K. NEVIN. (2006) Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. Alimentary Pharmacology and Therapeutics 23:4, 521-529
CrossRef41
2006. Clarithromycin. , 799-805.
CrossRef42
Per C. Valle, Ragnar K. Breckan, Anil Amin, Magnhild Gangsøy Kristiansen, Einar Husebye, Kåre Nordgård, Liisa Mortensen, Odd A. Kildahl-Andersen, Anna M. Wessel-Berg. (2006) “Test, score and scope”: A selection strategy for safe reduction of upper gastrointestinal endoscopies in young dyspeptic patients referred from primary care. Scandinavian Journal of Gastroenterology 41:2, 161-169
CrossRef43
HUCK JOO TAN, ABDUL MANAF RIZAL, MOHAMED-YUSOFF ROSMADI, KHEAN-LEE GOH. (2006) Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia. Journal of Gastroenterology and Hepatology 21:1, 110-115
CrossRef44
RAKESH K TANDON. (2006) Journal of Gastroenterology and Hepatology : 20 years and gaining momentum. Journal of Gastroenterology and Hepatology 21:1, 3-5
CrossRef45
Francesco Di Mario, Nicoletta Stefani, Nadia Dal Bò, Massimo Rugge, Alberto Pilotto, Giulia Martina Cavestro, Lucas Giovanni Cavallaro, Angelo Franzé, Gioacchino Leandro. (2005) Natural Course of Functional Dyspepsia After Helicobacter pyloriEradication: A Seven-Year Survey. Digestive Diseases and Sciences 50:12, 2286-2295
CrossRef46
Bruce E. Stabile, Brian R. Smith, David L. Weeks. (2005) Helicobacter pylori Infection and Surgical Disease—Part II. Current Problems in Surgery 42:12, 804-862
CrossRef47
Nicholas J. Talley, Nimish B. Vakil, Paul Moayyedi. (2005) American Gastroenterological Association Technical Review on the Evaluation of Dyspepsia. Gastroenterology 129:5, 1756-1780
CrossRef48
Derick J. Christian, Jo Buyske. (2005) Current Status of Antireflux Surgery. Surgical Clinics of North America 85:5, 931-947
CrossRef49
Anna Garc??a-Alt??s, Rosa Rota, Merc?? Barenys, ??gueda Abad, Victor Moreno, Joan M.V. Pons, Josep M. Piqu??. (2005) Cost-effectiveness of a ???score and scope??? strategy for the management of dyspepsia. European Journal of Gastroenterology & Hepatology 17:7, 709-719
CrossRef50
Sander J.O. Veldhuyzen van Zanten, Naoki Chiba, David Armstrong, Alan Barkun, Alan Thomson, Sandra Smyth, Sergio Escobedo, Joanna Lee, Paul Sinclair. (2005) A Randomized Trial Comparing Omeprazole, Ranitidine, Cisapride, or Placebo in Helicobacter pylori Negative, Primary Care Patients with Dyspepsia: The CADET-HN Study. The American Journal of Gastroenterology 100:7, 1477-1488
CrossRef51
Craig A. Friesen, Zhiyue Lin, Robert Garola, Linda Andre, Nancy Burchell, Anne Moore, Charles C. Roberts, Richard W. McCallum. (2005) Chronic Gastritis Is Not Associated with Gastric Dysrhythmia or Delayed Solid Emptying in Children with Dyspepsia. Digestive Diseases and Sciences 50:6, 1012-1018
CrossRef52
E. A. Ott, L. E. Mazzoleni, M. I. Edelweiss, G. B. Sander, A. C. Wortmann, A. L. Theil, G. Somm, A. Cartell, L. F. Rivero, D. M. Uchoa, C. F. Francesconi, J. C. Prolla. (2005) Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Alimentary Pharmacology and Therapeutics 21:10, 1231-1239
CrossRef53
Jan Tack, K J Lee. (2005) Pathophysiology and Treatment of Functional Dyspepsia. Journal of Clinical Gastroenterology 39:Supplement 3, S211-S216
CrossRef54
A. Pietroiusti, I. Luzzi, M. J. Gomez, A. Magrini, A. Bergamaschi, A. Forlini, A. Galante. (2005) Helicobacter pylori duodenal colonization is a strong risk factor for the development of duodenal ulcer. Alimentary Pharmacology and Therapeutics 21:7, 909-915
CrossRef55
Riccardo Marmo, Gianluca Rotondano, Roberto Piscopo, Maria Antonia Bianco, Paola Russo, Paola Capobianco, Livio Cipolletta. (2005) Combination of Age and Sex Improves the Ability to Predict Upper Gastrointestinal Malignancy in Patients with Uncomplicated Dyspepsia: A Prospective Multicentre Database Study. The American Journal of Gastroenterology 100:4, 784-791
CrossRef56
Antonio Ruiz García, Francisco Javier Gordillo López, Juan Carlos Hermosa Hernán, Ezequiel Arranz Martínez, José Enrique Villares Rodríguez. (2005) Efecto del tratamiento erradicador en pacientes con dispepsia funcional e infección por Helicobacter pylori: ensayo clínico aleatorizado frente a placebo. Medicina Clínica 124:11, 401-405
CrossRef57
S. E. Rubesin, E. E. Furth, M. S. Levine. (2005) Gastritis from NSAIDS to Helicobacter pylori. Abdominal Imaging 30:2, 142-159
CrossRef58
M.T. Cuddihy, G.R. Locke, D. Wahner-Roedler, R. Dierkhising, A.R. Zinsmeister, K Hall Long, N.J. Talley. (2005) Dyspepsia management in primary care: a management trial. International Journal of Clinical Practice 59:2, 194-201
CrossRef59
P Moayyedi, S Soo, J Deeks, B Delaney, A Harris, M Innes, R Oakes, S Wilson, A Roalfe, C Bennett, D Forman, Paul Moayyedi. 2005. Eradication of Helicobacter pylori for non-ulcer dyspepsia. .
CrossRef60
Sang In Lee. (2005) Functional Dyspepsia. Journal of the Korean Medical Association 48:1, 48
CrossRef61
Hidekazu Suzuki, Toshifumi Hibi. (2005) Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opinion on Pharmacotherapy 6:1, 59-67
CrossRef62
Jan Tack, Raf Bisschops, Giovanni Sarnelli. (2004) Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127:4, 1239-1255
CrossRef63
Merja Ashorn, Tiina R??g??, Jorma Kokkonen, Tarja Ruuska, Hilpi Rautelin, Riitta Karikoski. (2004) Symptomatic Response to Helicobacter Pylori Eradication in Children With Recurrent Abdominal Pain:. Journal of Clinical Gastroenterology 38:8, 646-650
CrossRef64
Enrico Corazziari. (2004) Definition and epidemiology of functional gastrointestinal disorders. Best Practice & Research Clinical Gastroenterology 18:4, 613-631
CrossRef65
Kwang-Jae Lee, S. Kindt, Jan Tack. (2004) Pathophysiology of functional dyspepsia. Best Practice & Research Clinical Gastroenterology 18:4, 707-716
CrossRef66
Suzanne Timmons, Richard Liston, Kieran J. Moriarty. (2004) Functional Dyspepsia: Motor Abnormalities, Sensory Dysfunction, and Therapeutic Options. The American Journal of Gastroenterology 99:4, 739-749
CrossRef67
Limas Kupcinskas, Laimas Jonaitis, Gediminas Kiudelis. (2004) A 1 year follow-up study of the consequences of Helicobacter pylori eradication in duodenal ulcer patients. European Journal of Gastroenterology & Hepatology 16:4, 369-374
CrossRef68
N. S. Abraham, P. Moayyedi, B. Daniels, S. J. O. Veldhuyzen Van Zanten. (2004) The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Alimentary Pharmacology and Therapeutics 19:6, 631-641
CrossRef69
Craig A. Friesen, Gregory L. Kearns, Linda Andre, Mark Neustrom, Charles C. Roberts, Susan M. Abdel-Rahman. (2004) Clinical Efficacy and Pharmacokinetics of Montelukast in Dyspeptic Children with Duodenal Eosinophilia. Journal of Pediatric Gastroenterology and Nutrition 38:3, 343-351
CrossRef70
G. Treiber, M. Schwabe, S. Ammon, S. Walker, U. Klotz, P. Malfertheiner. (2004) Dyspeptic symptoms associated with Helicobacter pylori infection are influenced by strain and host specific factors. Alimentary Pharmacology and Therapeutics 19:2, 219-231
CrossRef71
Henry P. Parkman. 2004. Functional (Non-Ulcer) Dyspepsia. , 75-79.
CrossRef72
FULL-YOUNG CHANG, CHING-LIANG LU, CHIH-YEN CHEN, JIING-CHYUAN LUO, KANG LIH JIUM, SHOU-DONG LEE. (2003) Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer. Journal of Gastroenterology and Hepatology 18:11, 1250-1256
CrossRef73
Ana Guti??rrez, Luis Rodrigo, Sabino Riestra, Eloy Fern??ndez, Valle Cadahia, Rafael Tojo, Dolores Fuentes, Pilar Ni??o, Jose Luis Olcoz. (2003) Quality of life in patients with functional dyspepsia. European Journal of Gastroenterology & Hepatology 15:11, 1175-1181
CrossRef74
H. O'Connor, S. Sebastian. (2003) The burden of Helicobacter pylori infection in Europe. Alimentary Pharmacology and Therapeutics 18:s3, 38-44
CrossRef75
Rex W. Force. (2003) Evidence-Based Medicine and Information Mastery: Application for Acute Gastrointestinal Conditions. Pharmacotherapy 23:10 Part 2, 61S-67S
CrossRef76
P. Malfertheiner, J. MOssner, W. Fischbach, P. Layer, A. Leodolter, M. Stolte, K. Demleitner, W. Fuchs. (2003) Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Alimentary Pharmacology and Therapeutics 18:6, 615-625
CrossRef77
T. Kamada, K. Haruma, J. Hata, H. Kusunoki, A. Sasaki, M. Ito, S. Tanaka, M. Yoshihara. (2003) The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Alimentary Pharmacology and Therapeutics 18:2, 245-252
CrossRef78
Dietrich Rothenbacher, Hermann Brenner. (2003) Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes and Infection 5:8, 693-703
CrossRef79
YOUNG-WOON CHANG, SUN-KEE MIN, KYUNG-JIN KIM, YO-SEOB HAN, JOO-HEE LEE, SEOK-HO DONG, HYO-JONG KIM, BYUNG-HO KIM, JOUNG-IL LEE, RIN CHANG. (2003) Delta 13 C-urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia. Journal of Gastroenterology and Hepatology 18:6, 726-731
CrossRef80
Magnus Simrén, Jan Tack. (2003) Functional dyspepsia: evaluation and treatment. Gastroenterology Clinics of North America 32:2, 577-599
CrossRef81
Kenneth R. McQuaid. (2003) Eradication of Helicobacter pylori in Nonulcer Dyspepsia. Journal of Clinical Gastroenterology 36:4, 291-294
CrossRef82
R. J.F. Laheij, L. G.M. van Rossum, A. L.M. Verbeek, J. B.M.J. Jansen. (2003) Helicobacter pylori Infection Treatment of Nonulcer Dyspepsia. Journal of Clinical Gastroenterology 36:4, 315-320
CrossRef83
Hans-Joachim Ulmer, Andree Beckerling, Gudrun Gatz. (2003) Recent Use of Proton Pump Inhibitor-Based Triple Therapies for the Eradication of H. pylori: A Broad Data Review. Helicobacter 8:2, 95-104
CrossRef84
H. H.-X. Xia, N. J. Talley, A. L. Blum, C. A. O'Morain, M. Stolte, E. Bolling-Sternevald, H. M. Mitchell. (2003) Clinical and pathological implications of IgG antibody responses toHelicobacter pyloriand its virulence factors in non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics 17:7, 935-943
CrossRef85
Karl M. Hoffmann, Andreas J. Eherer, Günter J. Krejs. (2003) Are dyspeptic symptoms linked to Helicobacter pylori? A prospective cohort study among medical students. Wiener Klinische Wochenschrift 115:5-6, 175-178
CrossRef86
F. Perri, V. Festa, E. Grossi, N. Garbagna, G. Leandro, A. Andriulli. (2003) Dyspepsia and Helicobacter pylori infection: a prospective multicentre observational study. Digestive and Liver Disease 35:3, 157-164
CrossRef87
N. Broutet, S. Tchamgoue, E. Pereira, H. Lamouliatte, R. Salamon, F. Megraud. (2003) Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Alimentary Pharmacology and Therapeutics 17:1, 99-109
CrossRef88
Nimish Vakil. (2002) Nonulcer dyspepsia. Current Gastroenterology Reports 4:6, 455-458
CrossRef89
Suerbaum, Sebastian, Michetti, Pierre, . (2002) Helicobacter pylori Infection. New England Journal of Medicine 347:15, 1175-1186
Full Text90
D. McNamara, M. Buckley, J. Gilvarry, C. O'Morain. (2002) Does Helicobacter pylori Eradication Affect Symptoms in Nonulcer Dyspepsia: A 5-Year Follow-Up Study. Helicobacter 7:5, 317-321
CrossRef91
M. Rosandic, V. Pilas, M. Bevanda, V. Falisevac, B. Korac. (2002) Quantification of Helicobacter pylori resistance in functional and organic dyspepsia. Journal of Clinical Pharmacy and Therapeutics 27:5, 353-355
CrossRef92
Craig A. Friesen, Linda Andre, Robert Garola, Charles Hodge, Charles Roberts. (2002) Activated Duodenal Mucosal Eosinophils in Children With Dyspepsia: A Pilot Transmission Electron Microscopic Study. Journal of Pediatric Gastroenterology and Nutrition 35:3, 329-333
CrossRef93
P. Malfertheiner, H. J. O'Connor, R. M. Genta, P. Unge, A. T. R. Axon. (2002) Helicobacter pylori and clinical risks-focus on gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics 16:s3, 1-10
CrossRef94
B. I. Hallerback, G. Bommelaer, E. Bredberg, M. Campbell, M. Hellblom, K. Lauritsen, M. Wienbeck, L. -L. Holmgren. (2002) Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Alimentary Pharmacology and Therapeutics 16:5, 959-967
CrossRef95
A. Shiotani, M. Iguchi, I. Inoue, H. Magari, K. Yanaoka, H. Tamai, S. Kitauchi, M. Ichinose. (2002) Association between gastric myoelectrical activity and intraluminal nitric oxide. Alimentary Pharmacology and Therapeutics 16:s2, 44-51
CrossRef96
Judy B. Splawski. (2002) Helicobacter pylori and Nonulcer Dyspepsia: Is There a Relation?. Journal of Pediatric Gastroenterology and Nutrition 34:3, 274
CrossRef97
N. J. Talley, C. Quan. (2002) Helicobacter pylori and nonulcer dyspepsia. Alimentary Pharmacology and Therapeutics 16:s1, 58-65
CrossRef98
Kashyap V. Panganamamula, Robert S. Fisher, Henry P. Parkman. (2002) Functional (nonulcer) dyspepsia. Current Treatment Options in Gastroenterology 5:2, 153-160
CrossRef99
Aliye Uc, Sonny K. F. Chong. (2002) Treatment of Helicobacter pylori Gastritis Improves Dyspeptic Symptoms in Children. Journal of Pediatric Gastroenterology and Nutrition 34:3, 281-285
CrossRef100
P. Malfertheiner, F. Megraud, C. O'Morain, A. P. S. Hungin, R. Jones, A. Axon, D. Y. Graham, G. Tytgat, . (2002) Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Alimentary Pharmacology and Therapeutics 16:2, 167-180
CrossRef101
G. Manes, A. Balzano, P. Marone, M. Lioniello, S. Mosca. (2002) Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system: a prospective observational study based on the Maastricht guidelines. Alimentary Pharmacology and Therapeutics 16:1, 105-110
CrossRef102
Ahmed Madisch, Jürgen Hotz, Gabriele Grabowski, Angelika Guth, Peter Malfertheiner, Klaus Plein, Berthold Schneider. (2002) Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study. European Journal of Gastroenterology & Hepatology 14:1, 61-69
CrossRef103
F. Bazzoli, G. Bianchi Porro, G. Maconi, M. Molteni, P. Pozzato, R.M. Zagari. (2002) Treatment of Helicobacter pylori infection. indications and regimens: an update. Digestive and Liver Disease 34:1, 70-83
CrossRef104
R. A Wallace, P. M Webb, P. J Schluter. (2002) Environmental, medical, behavioural and disability factors associated with Helicobacter pylori infection in adults with intellectual disability. Journal of Intellectual Disability Research 46:1, 51-60
CrossRef105
A. Otto Quartero, Mattijs E. Numans, Marcel W. M. Post, Ruut A. de Melker, Niek J. de Wit. (2002) One-year prognosis of primary care dyspepsia: predictive value of symptom pattern, Helicobacter pylori and GP management. European Journal of Gastroenterology & Hepatology 14:1, 55-60
CrossRef106
Kiichi Satoh. (2002) Indications forHelicobacter pylori eradication therapy and firstline therapy regimen in Japan: recommendation by the Japanese Society forHelicobacter Research. Journal of Gastroenterology 37:S13, 34-38
CrossRef107
Neal S. Goldstein. (2002) Chronic Inactive Gastritis and Coccoid Helicobacter pylori in Patients Treated for Gastroesophageal Reflux Disease or With H pylori Eradication Therapy. American Journal of Clinical Pathology 118:5, 719-726
CrossRef108
D. Williams, P. O'Kelly, A. Kelly, J. Feely. (2001) Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care. Alimentary Pharmacology and Therapeutics 15:11, 1769-1775
CrossRef109
N. J. Talley, D. S. Riff, H. Schwartz, S. P. Marcuard. (2001) Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 15:10, 1603-1611
CrossRef110
J. Koskenpato, M. Farkkila, P. Sipponen. (2001) Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. The American Journal of Gastroenterology 96:10, 2866-2872
CrossRef111
Me Numans, Lewin-Van den Broeck, J W M Muris. (2001) Maagklachten bij de huisarts, is er wel nieuws?. Huisarts en Wetenschap 44:9, 359-363
CrossRef112
Masahiro Asaka, Kiichi Satoh, Kentaro Sugano, Toshiro Sugiyama, Shin-ichi Takahashi, Yoshihiro Fukuda, Hiroyoshi Ota, Kazushige Murakami, Ken Kimura, Takashi Shimoyama. (2001) Guidelines in the Management of Helicobacter pylori Infection in Japan. Helicobacter 6:3, 177-186
CrossRef113
S. Bruley Des Varannes, J. F. Flejou, R. Colin, M. Zaim, A. Meunier, C. Bidaut-Mazel. (2001) There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Alimentary Pharmacology and Therapeutics 15:8, 1177-1185
CrossRef114
Malcolm Robinson. (2001) Dyspepsia: challenges in diagnosis and selection of treatment. Clinical Therapeutics 23:8, 1130-1144
CrossRef115
William L. Hasler. (2001) Augmented visceral perception. Current Treatment Options in Gastroenterology 4:4, 339-349
CrossRef116
Linda Rabeneck, Karon F Cook, Kimberly Wristers, Julianne Souchek, Terri Menke, Nelda P Wray. (2001) SODA (severity of dyspepsia assessment). Journal of Clinical Epidemiology 54:8, 755-765
CrossRef117
Carlos A. Pellegrini. (2001) Delayed Gastric Emptying in Patients with Abnormal Gastroesophageal Reflux. Annals of Surgery 234:2, 147-148
CrossRef118
T. Azuma, Y. Ito, H. Suto, M. Ohtani, M. Dojo, A. Muramatsu, M. Kuriyama, T. Kato. (2001) The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Alimentary Pharmacology and Therapeutics 15:6, 805-811
CrossRef119
J.R. Malagelada. (2001) The continuing dilemma of dyspepsia. Alimentary Pharmacology and Therapeutics 15:s1, 6-9
CrossRef120
R. Meier, A. Wettstein, J. Drewe, H. R. Geiser, . (2001) Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics 15:6, 851-855
CrossRef121
F. Cremonini, A. Gasbarrini, A. Armuzzi, G. Gasbarrini. (2001) Helicobacter pylori-related diseases. European Journal of Clinical Investigation 31:5, 431-437
CrossRef122
Pippa E. S. Bowie, Rosamond A. Cox, Andrew R. Davidson, Andrew Steel. (2001) Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastro-duodenoscopy workload sustained?. European Journal of Gastroenterology & Hepatology 13:5, 541-545
CrossRef123
Thomas F. Imperiale. (2001) IF THERE IS NO ULCER, DON'T LOOK FOR THE ???BUG???. Evidence-Based Gastroenterology 2:2, 61-62
CrossRef124
Benjamin D. Gold. (2001) New approaches to helicobacter pylori infection in children. Current Gastroenterology Reports 3:3, 235-247
CrossRef125
Nicholas J. Talley. (2001) Therapeutic Options in Nonulcer Dyspepsia. Journal of Clinical Gastroenterology 32:4, 286-293
CrossRef126
Akira Kawamura, Kyoichi Adachi, Toshiharu Takashima, Mitsuyoshi Murao, Tomoko Katsube, Mika Yuki, Makoto Watanabe, Yoshikazu Kinoshita. (2001) Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. Journal of Gastroenterology and Hepatology 16:4, 384-388
CrossRef127
Ching-Chu Lo, Ping-I Hsu, Gin-Ho Lo, Kwok-Hung Lai, Jin-Shiung Cheng, Huei-Hwa Tseng, Chiun-Ku Lin, Hoi-Hung Chan, Ya-Yu Wang, Ming-Kun Ku, Chi-Pin Lin, Nan-Jing Peng, Eileen Jea Chien. (2001) Comparison of clinical, serological and histological findings between non-ulcer dyspepsia patients with and without Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 16:3, 276-281
CrossRef128
Hermann Brenner, Günter Bode, Guido Adler, Albrecht Hoffmeister, Wolfgang Koenig, and Dietrich Rothenbacher. (2001) Alcohol as a Gastric Disinfectant? The Complex Relationship between Alcohol Consumption and Current Helicobacter pylori Infection. Epidemiology 12:2, 209-214
CrossRef129
P.-I. Hsu, K.-H. Lai, H.-H. Tseng, G.-H. Lo, C.-C. Lo, C.-K. Lin, J.-S. Cheng, H.-H. Chan, M.-K. Ku, N.-J. Peng, E.-J. Chien, W. Chen, P.-N. Hsu. (2001) Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Alimentary Pharmacology and Therapeutics 15:2, 195-201
CrossRef130
Peter W. Groeneveld, Tracy A. Lieu, A. Mark Fendrick, Leo B. Hurley, Lynn M. Ackerson, Theodore R. Levin, James E. Allison. (2001) Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia1. The American Journal of Gastroenterology 96:2, 338-347
CrossRef131
Harry Hua-Xiang Xia, Benjamin Chun Yu Wong, Nicholas J Talley, Shiu Kum Lam. (2001) Helicobacter pylori infection - current treatment practice. Expert Opinion on Pharmacotherapy 2:2, 253-266
CrossRef132
Anne M. Rentz, Carmelina Battista, Elyse Trudeau, Robert Jones, Patricia Robinson, Sheldon Sloan, Sonika Mathur, Lori Frank, Dennis A. Revicki. (2001) Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies. PharmacoEconomics 19:4, 349-363
CrossRef133
Maxwell A. Asante. (2001) Optimal Management of Patients With Non-Ulcer Dyspepsia. Drugs & Aging 18:11, 819-826
CrossRef134
Hartley Cohen. (2000) Peptic Ulcer and Helicobacter Pylori. Gastroenterology Clinics of North America 29:4, 775-789
CrossRef135
K.E.L. McColl. (2000) Helicobacter pylori and dyspepsia. Pro and against. Digestive and Liver Disease 32, 199-201
CrossRef136
Deirdre A. Mc Namara, Martin Buckley, Colm A. O'Morain. (2000) Nonulcer Dyspepsia. Gastroenterology Clinics of North America 29:4, 807-818
CrossRef137
Joshua J. Ofman. (2000) What have we learned from recent dyspepsia trials?. Current Gastroenterology Reports 2:6, 471-477
CrossRef138
Benjamin D. Gold, Richard B. Colletti, Myles Abbott, Steven J. Czinn, Yoram Elitsur, Eric Hassall, Colin Macarthur, John Snyder, Philip M. Sherman. (2000) Helicobacter pylori Infection in Children: Recommendations for Diagnosis and Treatment. Journal of Pediatric Gastroenterology and Nutrition 31:5, 490-497
CrossRef139
V. Stanghellini, C. Tosetti, G. Barbara, R. De Giorgio, B. Salvioli, R. Corinaldesi. (2000) The continuing dilemma of dyspepsia. Alimentary Pharmacology and Therapeutics 14:s3, 23-30
CrossRef140
Gnj Tytgat. (2000) Helicobacter pylori: Past, present and future. Journal of Gastroenterology and Hepatology 15:s3, G30-G33
CrossRef141
A. T. R. Axon. (2000) Treatment of Helicobacter pylori: an overview. Alimentary Pharmacology and Therapeutics 14:s3, 1-6
CrossRef142
G. N. J. Tytgat. (2000) Helicobacter pylori: where are we and where are we going?. Alimentary Pharmacology and Therapeutics 14:s3, 55-58
CrossRef143
Bernard Coulie, Michael Camilleri. (2000) New therapies for functional bowel diseases. Current Gastroenterology Reports 2:5, 355-363
CrossRef144
E. Hentschel. (2000) Therapie der Helicobacter pylori-Infektion*. Acta Medica Austriaca 27:4, 104-108
CrossRef145
Mark W. Whitehead, Rosemary H. Phillips, Christine E. Sieniawska, H. Trevor Delves, Paul T. Seed, Richard P.H. Thompson, Jonathan J. Powell. (2000) Double-Blind Comparison of Absorbable Colloidal Bismuth Subcitrate and Nonabsorbable Bismuth Subnitrate in the Eradication of Helicobacter pylori and the Relief of Nonulcer Dyspepsia. Helicobacter 5:3, 169-175
CrossRef146
Annmarie Touborg Lassen, Finn Møller Pedersen, Peter Bytzer, Ove B Schaffalitzky de Muckadell. (2000) Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. The Lancet 356:9228, 455-460
CrossRef147
Nimish Vakil. (2000) Heliobacter pylori and non-ulcer dyspepsia. Current Treatment Options in Gastroenterology 3:4, 341-345
CrossRef148
Paul W O′Toole, Michael C Lane, Steffen Porwollik. (2000) Helicobacter pylori motility. Microbes and Infection 2:10, 1207-1214
CrossRef149
Jerry M. Zuckerman. (2000) THE NEWER MACROLIDES: AZITHROMYCIN AND CLARITHROMYCIN. Infectious Disease Clinics of North America 14:2, 449-462
CrossRef150
Paul Moayyedi, David Forman, David Braunholtz, Richard Feltbower, Will Crocombe, Margaret Liptrott, Anthony Axon, . (2000) The proportion of upper gastrointestinal symptoms in the community associated with helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. The American Journal of Gastroenterology 95:6, 1448-1455
CrossRef151
Javier P. Gisbert, Jose Maria Pajares. (2000) Helicobacter pylori"Test-and-Scope" Strategy for Dyspeptic Patients. Helicobacter 5:2, 57-68
CrossRef152
Robert Janknegt, Leopold G.J.B. Engels. (2000) Formulary Management of Eradication Therapies for Helicobacter pylori. Disease Management and Health Outcomes 7:5, 251-266
CrossRef153
Xia, Kalantar, Mitchell, Talley. (2000) Can Helicobacter pylori serology still be applied as a surrogate marker to identify peptic ulcer disease in dyspepsia?. Alimentary Pharmacology and Therapeutics 14:5, 615-624
CrossRef154
Wayne Hc Hu, Shiu-Kum Lam. (2000) Helicobacter pylori and dyspepsia: Still an unresolved controversy?. Journal of Gastroenterology and Hepatology 15:5, 470-472
CrossRef155
Hession, Malagelada. (2000) Review article: the initial management of uninvestigated dyspepsia in younger patients-the value of symptom-guided strategies should be reconsidered. Alimentary Pharmacology and Therapeutics 14:4, 379-388
CrossRef156
Hiroto Miwa, Nobuhiro Sato. (2000) Functional dyspepsia and Helicobacter pylori infection: A recent consensus up to 1999. Journal of Gastroenterology and Hepatology 15:s1, 60-65
CrossRef157
John Danesh, Roy E Pounder. (2000) Eradication of Helicobacter pylori and non-ulcer dyspepsia. The Lancet 355:9206, 766-767
CrossRef158
Miwa, Hirai, Nagahara, Murai, Nishira, Kikuchi, Takei, Watanabe, Sato. (2000) Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Alimentary Pharmacology and Therapeutics 14:3, 317-324
CrossRef159
(2000) Absence of Benefit of Eradicating Helicobacter pylori in Patients with Nonulcer Dyspepsia. New England Journal of Medicine 342:8, 589-590
Full Text160
T. Murai, H. Miwa, R. Ohkura, R. Iwazaki, A. Nagahara, K. Sato, T. Yamada, K. Ota, H. Tanaka, M. Kawabe, T. Minowa, Y. Takei, A. Miyazaki, N. Sato. (2000) The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Alimentary Pharmacology and Therapeutics 14:Suppl. 1, 161-165
CrossRef161
Christine A. Wanke. (2000) The association of Helicobacter pylori infection with nonulcer dyspepsia. Current Infectious Disease Reports 2:1, 53-54
CrossRef162
M.Michael Wolfe, George Sachs. (2000) Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118:2, S9-S31
CrossRef163
Brendan Drumm, Sibylle Koletzko, Giuseppina Oderda. (2000) Helicobacter pylori Infection in Children: A Consensus Statement. Journal of Pediatric Gastroenterology and Nutrition 30:2, 207-213
CrossRef164
Kenneth McColl. (2000) Should Non-Invasive Helicobacter pylori Testing Replace Endoscopy in Investigation of Dyspepsia?. Helicobacter 5:S1, 11-15
CrossRef165
Van Der Wouden, Thijs, Van Zwet, Kleibeuker. (2000) Review article: nitroimidazole resistance in Helicobacter pylori. Alimentary Pharmacology and Therapeutics 14:1, 7-14
CrossRef166
Nimish Vakil, Mae F. Go. (2000) Treatment of Helicobacter pylori infection. Current Opinion in Gastroenterology 16:1, 32-39
CrossRef167
Alan B. R. Thomson. (1999) Therapy for H. pylori infection. Current Gastroenterology Reports 1:6, 518-523
CrossRef168
Johann Hammer, Nicholas J. Talley. (1999) Nonulcer dyspepsia. Current Opinion in Gastroenterology 15:6, 492
CrossRef169
Mitchell L. Schubert. (1999) Stomach and duodenum. Current Opinion in Gastroenterology 15:6, 455
CrossRef170
Tan, G. Den Hartog, Mulder. (1999) Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication. Alimentary Pharmacology and Therapeutics 13:11, 1519-1522
CrossRef171
J.A. Louw, I.N. Marks. (1999) The treatment of peptic ulcer disease. Current Opinion in Gastroenterology 15:6, 497
CrossRef172
Talley, Nicholas J., Vakil, Nimish, Ballard, E. David, Fennerty, M. Brian, . (1999) Absence of Benefit of Eradicating Helicobacter pylori in Patients with Nonulcer Dyspepsia. New England Journal of Medicine 341:15, 1106-1111
Full Text173
G. Richard Locke. (1999) Nonulcer Dyspepsia: What It Is and What It Is Not. Mayo Clinic Proceedings 74:10, 1011-1015
CrossRef174
G R Locke. (1999) Nonulcer dyspepsia: what it is and what it is not.. Mayo Clinic Proceedings 74:10, 1011-1014
CrossRef175
Talley, Axon, Bytzer, Holtmann, Lam, S. Velohuyzen Van Zanten. (1999) Management of uninvestigated and functional dyspepsia: a working party report for the World Congresses of Gastroenterology 1998. Alimentary Pharmacology and Therapeutics 13:9, 1135-1148
CrossRef176
Peiyi Wang, Richard Adair. (1999) Helicobacter pylori in Immigrants from East Africa. Journal of General Internal Medicine 14:9, 567-568
CrossRef177
Nicholas J Talley. (1999) Non-ulcer dyspepsia. Current Treatment Options in Gastroenterology 2:4, 307-312
CrossRef178
(1999) Helicobacter pylori and Nonulcer Dyspepsia. New England Journal of Medicine 340:19, 1508-1511
Full Text179
William D. Chey. (1999) Helicobacter Pylori. Current Treatment Options in Gastroenterology 2:3, 171-181
CrossRef180
Javier P. Gisbert, José María Pajar. (1999) Helicobacter pylori 'Test-and-Treat' Strategy for Dyspeptic Patients. Scandinavian Journal of Gastroenterology 34:7, 644-652
CrossRef181
Friedman, Lawrence S., . (1998) Helicobacter pylori and Nonulcer Dyspepsia. New England Journal of Medicine 339:26, 1928-1930
Full Text
